 |
24 Diseases |  |
3 Trials |
|
3 Trials |  |
144 News |  |
| 123» |
- | Trial completion, Trial completion date, Metastases: Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers (clinicaltrials.gov) - Sep 20, 2024
P2, N=32, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | Trial completion date: Jan 2026 --> Aug 2024
- | bintrafusp alfa (M7824) / EMD Serono, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic, ProstVac (rilimogene galvacirepvec) / Bavarian Nordic
Enrollment change: Combination Immunotherapy in Biochemically Recurrent Prostate Cancer (clinicaltrials.gov) - Jun 26, 2024
P2, N=40, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | Trial completion date: Jan 2026 --> Aug 2024 N=29 --> 40
- | bintrafusp alfa (M7824) / EMD Serono, SX-682 / Syntrix, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Trial completion, Combination therapy, Metastases: Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT) (clinicaltrials.gov) - Jun 11, 2024
P1/2, N=12, Completed, Sponsor: National Cancer Institute (NCI)
N=29 --> 40 Active, not recruiting --> Completed
- | Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Trial completion date, Surgery: Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery (clinicaltrials.gov) - Apr 25, 2024
P1, N=18, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Trial completion date: Apr 2024 --> Apr 2025
- || Panvac-VF (falimarev/inalimarev) / Bavarian Nordic, Opdivo (nivolumab) / BMS
Trial completion date, Trial primary completion date, Combination therapy, Metastases: HCRN GI16-288: A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC (clinicaltrials.gov) - Apr 19, 2024
P2, N=78, Active, not recruiting, Sponsor: Patrick Boland
Trial completion date: Apr 2024 --> Apr 2025 Trial completion date: Jun 2023 --> Dec 2024 | Trial primary completion date: Jun 2023 --> Mar 2024
- | bintrafusp alfa (M7824) / EMD Serono, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic, ProstVac (rilimogene galvacirepvec) / Bavarian Nordic
Trial completion date, Trial primary completion date: Combination Immunotherapy in Biochemically Recurrent Prostate Cancer (clinicaltrials.gov) - Feb 18, 2024
P2, N=29, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jun 2023 --> Dec 2024 | Trial primary completion date: Jun 2023 --> Mar 2024 Trial completion date: Jan 2024 --> Jan 2025 | Trial primary completion date: Jan 2024 --> Jan 2025
- | Enrollment closed, Enrollment change, Trial completion date, Metastases: Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers (clinicaltrials.gov) - Nov 14, 2023
P2, N=32, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jan 2024 --> Jan 2025 | Trial primary completion date: Jan 2024 --> Jan 2025 Completed --> Active, not recruiting | N=23 --> 32 | Trial completion date: Feb 2023 --> Jan 2026
- Panvac-VF (falimarev/inalimarev) / Bavarian Nordic, Imfinzi (durvalumab) / AstraZeneca
Trial termination, Combination therapy, Metastases: Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma (clinicaltrials.gov) - Oct 17, 2023
P1/2, N=8, Terminated, Sponsor: Georgetown University
Completed --> Active, not recruiting | N=23 --> 32 | Trial completion date: Feb 2023 --> Jan 2026 Active, not recruiting --> Terminated; Study closed due to lack of enrollment.
- | bintrafusp alfa (M7824) / EMD Serono, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic, ProstVac (rilimogene galvacirepvec) / Bavarian Nordic
Enrollment closed: Combination Immunotherapy in Biochemically Recurrent Prostate Cancer (clinicaltrials.gov) - Jul 20, 2023
P2, N=29, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Terminated; Study closed due to lack of enrollment. Recruiting --> Active, not recruiting
- | bintrafusp alfa (M7824) / EMD Serono, SX-682 / Syntrix, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Trial primary completion date, Combination therapy, Metastases: Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT) (clinicaltrials.gov) - May 8, 2023
P1/2, N=12, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Trial primary completion date: Oct 2021 --> Feb 2023
- | Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Trial completion date, Surgery: Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery (clinicaltrials.gov) - Apr 28, 2023
P1, N=18, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Oct 2021 --> Feb 2023 Trial completion date: Apr 2023 --> Apr 2024
- | Trial completion, Trial completion date, Trial primary completion date, Metastases: Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers (clinicaltrials.gov) - Mar 30, 2023
P2, N=23, Completed, Sponsor: National Cancer Institute (NCI)
Trial completion date: Apr 2023 --> Apr 2024 Active, not recruiting --> Completed | Trial completion date: Jul 2024 --> Feb 2023 | Trial primary completion date: Jul 2024 --> Oct 2022
- || Panvac-VF (falimarev/inalimarev) / Bavarian Nordic, Tecentriq (atezolizumab) / Roche
P2 data, Journal, Metastases: Phase II trial of CV301 vaccine combined with atezolizumab in advanced urothelial carcinoma. (Pubmed Central) - Feb 27, 2023
Patients exhibiting benefit demonstrated T-cell response to CEA and MUC-1. The trial illustrates the challenges in the development of vaccines, which should be guided by robust preclinical data.
- ||||| Panvac-VF (falimarev/inalimarev) / Bavarian Nordic, Opdivo (nivolumab) / Ono Pharma, BMS
Clinical: A5-3 📌 Another vaccine trial investigates CV301, (a vector based vax containing MUC1 & CEA) + nivolumab & chemotherapy for pts with resectable liver mets ! 📌Primary end point is 3-year OS & secondary endpoint include T cell clonality! #CRCTrialsChat @OncoAlert #CRCSM (Twitter) - Feb 16, 2023
- || Panvac-VF (falimarev/inalimarev) / Bavarian Nordic, Opdivo (nivolumab) / BMS
Trial primary completion date, Combination therapy, Metastases: HCRN GI16-288: A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC (clinicaltrials.gov) - Jan 19, 2023
P2, N=78, Active, not recruiting, Sponsor: Patrick Boland
The trial illustrates the challenges in the development of vaccines, which should be guided by robust preclinical data. Trial primary completion date: Dec 2022 --> Jun 2023
- |||| Clinical: #GI23 ➡️Several Ph 1 trials in CRC: ✅A Ph 1 trial of E7386, a CREB-binding protein/β-cat interaction inh, in pts mCRC 👁️Shunsuke Kondo, Abs 106, Pos F3 ✅A Ph II trial of IO w/ CV301, N-803, bintrafusp alfa, and M9241 in pts w/ mCRC 👁️DM Pastor, Abs 116, Pos F13 (Twitter) - Jan 16, 2023
- Panvac-VF (falimarev/inalimarev) / Bavarian Nordic, Imfinzi (durvalumab) / AstraZeneca
Trial completion date, Combination therapy, Metastases: Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma (clinicaltrials.gov) - Jan 10, 2023
P1/2, N=8, Active, not recruiting, Sponsor: Georgetown University
Trial primary completion date: Dec 2022 --> Jun 2023 Trial completion date: Dec 2023 --> Aug 2023
- Phase II evaluation of combination immunotherapy with CV301, N-803, bintrafusp alfa, and M9241 in patients with advanced small bowel and colorectal cancers. (On Demand | Level 1, West Hall; Poster Board No. F13) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_780;
P2
Preliminary clinical activity was observed in patients with advanced MSS/pMMR small bowel or CRC. Median OS was promising as compared to historical median survivals of 6-7 months following receipt of multiple lines of therapy.
- Panvac-VF (falimarev/inalimarev) / Bavarian Nordic, Opdivo (nivolumab) / Ono Pharma, BMS
HCRN GI16-288: A phase II trial of perioperative CV301 vaccination in combination with nivolumab and systemic chemotherapy for resectable hepatic-limited metastatic colorectal cancer—Preliminary efficacy and correlative results. (On Demand | Level 1, West Hall; Poster Board No. E20) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_767;
P2
Changes in T cells suggest a vaccine response. Clinical trial information: NCT03547999.
- | Enrollment closed, Enrollment change, Metastases: Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers (clinicaltrials.gov) - Dec 9, 2022
P2, N=23, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Clinical trial information: NCT03547999. Recruiting --> Active, not recruiting | N=80 --> 23
- |||||| Panvac-VF (falimarev/inalimarev) / Bavarian Nordic, Tecentriq (atezolizumab) / Roche
Clinical: Phase II trial of CV301 vaccine combined with atezolizumab in advanced #UrothelialCarcinoma. #BeyondTheAbstract with @sonpavde @AdventHealth. #ReadNow on UroToday > https://t.co/uqQQXrDTU6 @PGrivasMDPhD @maughanonc @BradMcG04 @xiaoweimd @MikeSchweizerMD @heatherhcheng (Twitter) - Nov 21, 2022
- |||||| Panvac-VF (falimarev/inalimarev) / Bavarian Nordic, Tecentriq (atezolizumab) / Roche
Clinical: Phase II trial of CV301 vaccine combined with atezolizumab in advanced #UrothelialCarcinoma. #BeyondTheAbstract with @sonpavde @AdventHealth. #ReadNow on UroToday > https://t.co/uqQQXrDTU6 @PGrivasMDPhD @maughanonc @BradMcG04 @xiaoweimd @MikeSchweizerMD @heatherhcheng (Twitter) - Oct 20, 2022
- |||||| Panvac-VF (falimarev/inalimarev) / Bavarian Nordic, Tecentriq (atezolizumab) / Roche
Clinical: Phase II trial of CV301 vaccine combined with atezolizumab in advanced #UrothelialCarcinoma. #BeyondTheAbstract with @sonpavde @AdventHealth. #ReadNow on UroToday > https://t.co/uqQQXrmj2y @PGrivasMDPhD @maughanonc @BradMcG04 @xiaoweimd @MikeSchweizerMD @heatherhcheng (Twitter) - Sep 21, 2022
- ||||| Panvac-VF (falimarev/inalimarev) / Bavarian Nordic, Tecentriq (atezolizumab) / Roche
Biomarker, Clinical: Disappointing activity of CV301 poxvirus vaccine (encoding MUC1, CEA, co-stimulatory B7.1, ICAM-1, LFA-3)+atezo in advanced #urothelialcarcinoma-need optimal selection of patients-earlier stage, biomarkers, optimal combinations @PGrivasMDPhD https://t.co/JfLt4jaD1g @urotoday (Twitter) - Sep 7, 2022
- || Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
P1 data, Journal, Combination therapy: Phase 1 Trial of CV301 in Combination with Anti-PD-1 Therapy in Non-Squamous Non-Small Cell Lung Cancer. (Pubmed Central) - Sep 3, 2022
P1
We conclude that CV301 administered with PD-1 inhibitors is safe and clinically active in patients with advanced NSCLC. The frequency or severity of AEs is not increased, including irAEs for each component of the combination.
- ||||| Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Clinical: CV301 (poxvirus vaccine encoding MUC1,CEA, co-stimulatory B7.1, ICAM-1, LFA-3)-poor activity in advanced #urothelialcarcinoma-need #precision medicine, better setting (?adjuvant)-collaboration @BavarianNordic @PGrivasMDPhD @maughanonc @BradMcG04 @OncoAlert https://t.co/0dBAwglX8R (Twitter) - Aug 23, 2022
- || Panvac-VF (falimarev/inalimarev) / Bavarian Nordic, Opdivo (nivolumab) / BMS
Trial primary completion date, Combination therapy, Metastases: HCRN GI16-288: A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC (clinicaltrials.gov) - Jul 12, 2022
P2, N=78, Active, not recruiting, Sponsor: Patrick Boland
The frequency or severity of AEs is not increased, including irAEs for each component of the combination. Trial primary completion date: Jun 2022 --> Dec 2022
- | bintrafusp alfa (M7824) / EMD Serono, SX-682 / Syntrix, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT) (clinicaltrials.gov) - Jul 12, 2022
P1/2, N=12, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jun 2022 --> Dec 2022 Trial completion date: Jun 2026 --> May 2024 | Trial primary completion date: Dec 2025 --> Oct 2021
- | Trial primary completion date, Metastases: Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers (clinicaltrials.gov) - May 25, 2022
P2, N=80, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jun 2026 --> May 2024 | Trial primary completion date: Dec 2025 --> Oct 2021 Trial primary completion date: Jul 2023 --> Jul 2024
- bintrafusp alfa (M7824) / EMD Serono, Merck (MSD), SX-682 / Syntrix, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Clinical responses in pancreaticobiliary cancer patients who received bintrafusp alfa (BA) or BA plus CXCR1/2 inhibitor (SX-682) plus CEA/MUC1-targted vaccine (CV301) () - May 12, 2022 - Abstract #ESMOGI2022ESMO_GI_300;
P1, P1/2
With this triplet, grade 3 bleeding was observed at a substantially higher rate than expected (rate of grade ≥ 3 bleeding = 8.6% with BA alone). In PBC patients, investigation of an ICB that does not potentiate bleeding, combined with SX-682 + CV301 (or other vaccine against the MUC1 and CEA tumor antigens) is warranted.
- ||| Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Enrollment change, Combination therapy, Metastases: CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer (clinicaltrials.gov) - Apr 27, 2022
P2, N=43, Completed, Sponsor: Bavarian Nordic
In PBC patients, investigation of an ICB that does not potentiate bleeding, combined with SX-682 + CV301 (or other vaccine against the MUC1 and CEA tumor antigens) is warranted. N=70 --> 43
- | Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Trial completion date, Trial primary completion date, Surgery: Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery (clinicaltrials.gov) - Apr 18, 2022
P1, N=18, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=70 --> 43 Trial completion date: Apr 2022 --> Apr 2023 | Trial primary completion date: Apr 2022 --> Sep 2021
- Panvac-VF (falimarev/inalimarev) / Bavarian Nordic, Imfinzi (durvalumab) / AstraZeneca
Trial primary completion date, Combination therapy, Metastases: Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma (clinicaltrials.gov) - Mar 31, 2022
P1/2, N=8, Active, not recruiting, Sponsor: Georgetown University
Trial completion date: Apr 2022 --> Apr 2023 | Trial primary completion date: Apr 2022 --> Sep 2021 Trial primary completion date: Dec 2021 --> Aug 2021
- |||| Panvac-VF (falimarev/inalimarev) / Bavarian Nordic, Tecentriq (atezolizumab) / Roche
Clinical: CV301 (poxvirus vaccine-targets CEA,MUC1)+atezo has insufficient efficacy & immune responses in advanced #bladdercancer-'off the shelf' tumor associated antigen vaccine is advantageous, but needs better patient selection, #PrecisionMedicine & better vaccine? #GU22 @PGrivasMDPhD (Twitter) - Mar 6, 2022
- ||||| Panvac-VF (falimarev/inalimarev) / Bavarian Nordic, Tecentriq (atezolizumab) / Roche
Clinical: Guru Sonpavde (@sonpavde) of @DanaFarber @harvardmed talks on the Phase 2 trial of CV301 vaccine plus atezolizumab in advanced #UrothelialCarcinoma Watch: 👉https://t.co/pk6dZqL74u👈 @ASCO #GU22 #BladderCancer (Twitter) - Feb 27, 2022
- || Panvac-VF (falimarev/inalimarev) / Bavarian Nordic, Opdivo (nivolumab) / BMS
Trial primary completion date, Combination therapy, Metastases: HCRN GI16-288: A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC (clinicaltrials.gov) - Jan 12, 2022
P2, N=78, Active, not recruiting, Sponsor: Kristen Spencer
Trial primary completion date: Dec 2021 --> Aug 2021 Trial primary completion date: Dec 2021 --> Jun 2022
- Panvac-VF (falimarev/inalimarev) / Bavarian Nordic, Tecentriq (atezolizumab) / Roche
Phase 2 trial of CV301 vaccine plus atezolizumab (Atezo) in advanced urothelial carcinoma (aUC). (In-Person & On Demand | Level 1, West Hall - G2) - Jan 5, 2022 - Abstract #ASCOGU2022ASCO_GU_565;
P2
CV301 + atezo exhibited an acceptable safety profile but did not demonstrate sufficient efficacy in pts with aUC as 1st-line therapy in cisplatin-ineligible pts or in the platinum-refractory setting. The development of effective vaccines to generate robust and durable responses as single agents and/or combined with anti-PD(L)1 remains an unmet need in aUC.
- | Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Trial completion date, Trial primary completion date, Surgery: Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery (clinicaltrials.gov) - Jan 5, 2022
P1, N=18, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
The development of effective vaccines to generate robust and durable responses as single agents and/or combined with anti-PD(L)1 remains an unmet need in aUC. Trial completion date: Dec 2021 --> Apr 2022 | Trial primary completion date: Dec 2021 --> Apr 2022
- | Enrollment open, Enrollment change, Metastases: Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers (clinicaltrials.gov) - Dec 22, 2021
P2, N=80, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Dec 2021 --> Apr 2022 | Trial primary completion date: Dec 2021 --> Apr 2022 Suspended --> Recruiting | N=14 --> 80
- | bintrafusp alfa (M7824) / EMD Serono, SX-682 / Syntrix, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Enrollment closed, Combination therapy, Metastases: Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT) (clinicaltrials.gov) - Nov 1, 2021
P1/2, N=8, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Suspended --> Recruiting | N=14 --> 80 Suspended --> Active, not recruiting
- | Enrollment change, Trial suspension, Metastases: Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers (clinicaltrials.gov) - Oct 19, 2021
P2, N=14, Suspended, Sponsor: National Cancer Institute (NCI)
Suspended --> Active, not recruiting N=80 --> 14 | Recruiting --> Suspended
- | bintrafusp alfa (M7824) / EMD Serono, SX-682 / Syntrix, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Enrollment change, Trial suspension, Combination therapy, Metastases: Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT) (clinicaltrials.gov) - Sep 8, 2021
P1/2, N=8, Suspended, Sponsor: National Cancer Institute (NCI)
N=80 --> 14 | Recruiting --> Suspended N=105 --> 8 | Recruiting --> Suspended
- ||| Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Trial completion, Trial completion date, Trial primary completion date, Combination therapy, Metastases: CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer (clinicaltrials.gov) - Aug 3, 2021
P2, N=70, Completed, Sponsor: Bavarian Nordic
N=105 --> 8 | Recruiting --> Suspended Active, not recruiting --> Completed | Trial completion date: Mar 2023 --> Feb 2021 | Trial primary completion date: Mar 2021 --> Nov 2020
- | Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Trial primary completion date, Surgery: Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery (clinicaltrials.gov) - Jul 6, 2021
P1, N=18, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | Trial completion date: Mar 2023 --> Feb 2021 | Trial primary completion date: Mar 2021 --> Nov 2020 Trial primary completion date: Jun 2021 --> Oct 2021
- || Panvac-VF (falimarev/inalimarev) / Bavarian Nordic, Opdivo (nivolumab) / BMS
Enrollment closed, Trial primary completion date, Combination therapy, Metastases: HCRN GI16-288: A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC (clinicaltrials.gov) - Apr 19, 2021
P2, N=78, Active, not recruiting, Sponsor: Kristen Spencer
Trial primary completion date: Jun 2021 --> Oct 2021 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2020 --> Dec 2021
- | Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Trial primary completion date, Surgery: Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery (clinicaltrials.gov) - Mar 18, 2021
P1, N=18, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2020 --> Dec 2021 Trial primary completion date: Mar 2021 --> Jun 2021
- |||| Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
you actually came up in another "historical" retweet over the weekend. Just didn't tag you. Hoping I'll be hearing more re CV301 at ASCO 21. for both CRC and Pancreatic cancer https://t.co/vL7FuRB8Jz (Twitter) - Feb 3, 2021
- | Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Trial primary completion date, Surgery: Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery (clinicaltrials.gov) - Nov 30, 2020
P1, N=18, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Mar 2021 --> Jun 2021 Trial primary completion date: Dec 2020 --> Mar 2021
- | bintrafusp alfa (M7824) / EMD Serono, SX-682 / Syntrix, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Enrollment open, Combination therapy, Metastases: Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT) (clinicaltrials.gov) - Nov 22, 2020
P1/2, N=105, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2020 --> Mar 2021 Not yet recruiting --> Recruiting
- ||| Panvac-VF (falimarev/inalimarev) / Bavarian Nordic, Imfinzi (durvalumab) / AstraZeneca
Enrollment closed, Enrollment change, Combination therapy, Metastases: Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma (clinicaltrials.gov) - Nov 4, 2020
P1/2, N=8, Active, not recruiting, Sponsor: Georgetown University
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=54 --> 8